Click Here to
News, Updates,
& More
Stay Up
to Date

Thyroid Cancer

Although the FDA approval of the 2 kinase inhibitors, lenvatinib (Lenvima) and sorafenib (Nexavar), has improved progression-free survival (PFS) rates, the responses to treatment with these agents are not durable and more treatments are needed.

Results 1 - 1 of 1